Jiangsu Hansoh Pharmaceutical Co., Ltd.

This study tests an investigational injection called HS-20094 in people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. About 204 participants will receive either the drug or a placebo for up to 52 weeks. The main goal is to see if the dr…

This early-stage study tests a new drug called HS-10587 in people with advanced solid tumors that have a missing MTAP gene. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 362 adults who have tried other treatments without suc…

This early-phase study tests a new drug called HS-10504 combined with other treatments in 400 people with advanced non-small cell lung cancer that has worsened after prior therapy. The goal is to find safe and effective doses and see how well the combination shrinks tumors. Parti…

This study tests an experimental drug called HS-10542 in people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 90 adults will receive either the drug or a placebo to see if it reduces protein in the urine, a sign of kidney damage. The goal is to con…

This study tests a new weekly injection called HS-20094 against an existing drug, dulaglutide, for people with type 2 diabetes whose blood sugar is not well controlled with metformin alone or with another diabetes pill. About 546 adults will receive one of the two injections for …

This study tests a new medicine called HS-10390 in 182 adults with chronic kidney disease. The goal is to see if it can lower protein levels in urine, a sign of kidney damage. Participants must already be on standard blood pressure medicines. The trial compares HS-10390 to an act…

This study tests a new drug called HS-10566 in people with high-risk bladder cancer that hasn't spread into the muscle wall. It is for those who cannot have or choose not to have their bladder removed. The study has two parts: first finding the best dose, then checking how well i…

This study tests a new drug called HS-10506 to help people with insomnia fall asleep faster and stay asleep longer. About 732 Chinese adults with insomnia will receive either the drug or a placebo for up to 84 days. The main goal is to see if the drug improves sleep measured by b…

This early-stage study will check if taking itraconazole (a common antifungal) changes how the body processes an experimental drug called HS-10506. Twenty healthy Chinese adults aged 18-45 will take HS-10506 alone and then with itraconazole. The goal is to gather safety and drug-…

This early-stage study tests the safety of a new drug called HS-20152 in 32 healthy adults aged 18 to 64. The drug targets the complement system, a part of the immune system. Researchers will monitor side effects and measure how the drug moves through the body. This study does no…

This early-stage study tests whether a single injection of HS-20136-2 is safe and tolerable in healthy adults aged 18-65. About 38 participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. No tre…